EffRx agrees distribution partnership in Malaysia
Freienbach/Kuala Lumpur - EffRx Pharmaceuticals has reached an exclusive licensing and distribution agreement for Binosto with Compai Pharma. Under the terms of this contract, Compai Pharma will be responsible for distribution activities in Malaysia for this medication. With this agreement, EffRx is seeking to expand its market position in Southeast Asia.
(CONNECT) EffRx Pharmaceuticals SA, a pharma firm based in Freienbach in the canton of Schwyz, Switzerland, has concluded an exclusive licensing and distribution agreement for its drug Binosto with the Malaysian company Compai Pharma. As detailed in a statement, Compai Pharma will be tasked with distributing the medication, which is used to treat osteoporosis in postmenopausal women, on the Malaysian market. With this new agreement, EffRx Pharmaceuticals is aiming to further expand its market position in Southeast Asia.
Binosto is a buffered effervescent alendronate tablet that is dissolved in water. The drug is used to treat osteoporosis in postmenopausal women and to strengthen bone mass in people with osteoporosis. EffRx has already commercialized Binosto in Europe, Asia and the Middle East.
“We are proud to partner with Compai Pharma to better serve patients with osteoporosis in Malaysia”, comments Victor Papavasileiou, EVP Corporate Development at EffRx Pharmaceuticals, before adding: “This partnership is a cornerstone of our growth strategy in Southeast Asia”. Mahesh Janarthanan, Marketing Director at Compai Pharma, believes that this agreement offers an opportunity to help people suffering from osteoporosis in Malaysia, who up to this point have been underserved in terms of available medications. ce/ww
